Clinical efficacy and safety of multidrug therapy including thrice weekly intravenous amikacin administration for Mycobacterium abscessus pulmonary disease in outpatient settings: A case series

Ho Namkoong, Kozo Morimoto, Tomoyasu Nishimura, Hiromu Tanaka, Hiroaki Sugiura, Yoshitake Yamada, Atsuko Kurosaki, Takanori Asakura, Shoji Suzuki, Hiroshi Fujiwara, Kazuma Yagi, Makoto Ishii, Sadatomo Tasaka, Tomoko Betsuyaku, Yoshihiko Hoshino, Atsuyuki Kurashima, Naoki Hasegawa

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Mycobacterium abscessus (M. abscessus) pulmonary disease is a refractory chronic infectious disease. Options for treating M. abscessus pulmonary disease are limited, especially in outpatient settings. Among parenteral antibiotics against M. abscessus, intravenous amikacin (AMK) is expected to be an effective outpatient antimicrobial therapy. This study evaluated the clinical efficacy and safety of intravenous AMK therapy in outpatients with M. abscessus pulmonary disease. Methods: This retrospective chart review of cases of M. abscessus pulmonary disease evaluated patient background data, AMK dosage and duration, sputum conversion, clinical symptoms radiological findings, and adverse events. M. massiliense was excluded on the basis of multiplex PCR assay. Results: Thirteen patients (2 men and 11 women) with M. abscessus pulmonary disease were enrolled at 2 hospitals. The median age at the initiation of intravenous AMK treatment was 65 years (range: 50-86 years). Patients received a median AMK dose of 12.5 mg/kg (range: 8.3-16.2 mg/kg) for a median duration of 4 months (range: 3-9 months). The addition of intravenous AMK led to sputum conversion in 10 of 13 patients, and 8 patients continued to have negative sputum status 1 year after treatment. Approximately half of the patients showed improvement on chest high-resolution computed tomography. There were no severe adverse events such as ototoxicity, vestibular toxicity, and renal toxicity. Conclusions: Thrice weekly intravenous AMK administration in outpatient settings is effective and safe for patients with M. abscessus pulmonary disease.

Original languageEnglish
Article number396
JournalBMC Infectious Diseases
Volume16
Issue number1
DOIs
Publication statusPublished - 2016 Aug 9

Fingerprint

Amikacin
Mycobacterium
Intravenous Administration
Lung Diseases
Outpatients
Safety
Sputum
Therapeutics
Multiplex Polymerase Chain Reaction
Communicable Diseases
Chronic Disease
Thorax
Tomography
Anti-Bacterial Agents
Kidney

Keywords

  • Amikacin
  • Intravenous therapy
  • Mycobacterium abscessus
  • Outpatient treatment
  • Rapid-growing mycobacterium

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Clinical efficacy and safety of multidrug therapy including thrice weekly intravenous amikacin administration for Mycobacterium abscessus pulmonary disease in outpatient settings : A case series. / Namkoong, Ho; Morimoto, Kozo; Nishimura, Tomoyasu; Tanaka, Hiromu; Sugiura, Hiroaki; Yamada, Yoshitake; Kurosaki, Atsuko; Asakura, Takanori; Suzuki, Shoji; Fujiwara, Hiroshi; Yagi, Kazuma; Ishii, Makoto; Tasaka, Sadatomo; Betsuyaku, Tomoko; Hoshino, Yoshihiko; Kurashima, Atsuyuki; Hasegawa, Naoki.

In: BMC Infectious Diseases, Vol. 16, No. 1, 396, 09.08.2016.

Research output: Contribution to journalArticle

Namkoong, Ho ; Morimoto, Kozo ; Nishimura, Tomoyasu ; Tanaka, Hiromu ; Sugiura, Hiroaki ; Yamada, Yoshitake ; Kurosaki, Atsuko ; Asakura, Takanori ; Suzuki, Shoji ; Fujiwara, Hiroshi ; Yagi, Kazuma ; Ishii, Makoto ; Tasaka, Sadatomo ; Betsuyaku, Tomoko ; Hoshino, Yoshihiko ; Kurashima, Atsuyuki ; Hasegawa, Naoki. / Clinical efficacy and safety of multidrug therapy including thrice weekly intravenous amikacin administration for Mycobacterium abscessus pulmonary disease in outpatient settings : A case series. In: BMC Infectious Diseases. 2016 ; Vol. 16, No. 1.
@article{b1b2863d50e444379b9977076457245c,
title = "Clinical efficacy and safety of multidrug therapy including thrice weekly intravenous amikacin administration for Mycobacterium abscessus pulmonary disease in outpatient settings: A case series",
abstract = "Background: Mycobacterium abscessus (M. abscessus) pulmonary disease is a refractory chronic infectious disease. Options for treating M. abscessus pulmonary disease are limited, especially in outpatient settings. Among parenteral antibiotics against M. abscessus, intravenous amikacin (AMK) is expected to be an effective outpatient antimicrobial therapy. This study evaluated the clinical efficacy and safety of intravenous AMK therapy in outpatients with M. abscessus pulmonary disease. Methods: This retrospective chart review of cases of M. abscessus pulmonary disease evaluated patient background data, AMK dosage and duration, sputum conversion, clinical symptoms radiological findings, and adverse events. M. massiliense was excluded on the basis of multiplex PCR assay. Results: Thirteen patients (2 men and 11 women) with M. abscessus pulmonary disease were enrolled at 2 hospitals. The median age at the initiation of intravenous AMK treatment was 65 years (range: 50-86 years). Patients received a median AMK dose of 12.5 mg/kg (range: 8.3-16.2 mg/kg) for a median duration of 4 months (range: 3-9 months). The addition of intravenous AMK led to sputum conversion in 10 of 13 patients, and 8 patients continued to have negative sputum status 1 year after treatment. Approximately half of the patients showed improvement on chest high-resolution computed tomography. There were no severe adverse events such as ototoxicity, vestibular toxicity, and renal toxicity. Conclusions: Thrice weekly intravenous AMK administration in outpatient settings is effective and safe for patients with M. abscessus pulmonary disease.",
keywords = "Amikacin, Intravenous therapy, Mycobacterium abscessus, Outpatient treatment, Rapid-growing mycobacterium",
author = "Ho Namkoong and Kozo Morimoto and Tomoyasu Nishimura and Hiromu Tanaka and Hiroaki Sugiura and Yoshitake Yamada and Atsuko Kurosaki and Takanori Asakura and Shoji Suzuki and Hiroshi Fujiwara and Kazuma Yagi and Makoto Ishii and Sadatomo Tasaka and Tomoko Betsuyaku and Yoshihiko Hoshino and Atsuyuki Kurashima and Naoki Hasegawa",
year = "2016",
month = "8",
day = "9",
doi = "10.1186/s12879-016-1689-6",
language = "English",
volume = "16",
journal = "BMC Infectious Diseases",
issn = "1471-2334",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Clinical efficacy and safety of multidrug therapy including thrice weekly intravenous amikacin administration for Mycobacterium abscessus pulmonary disease in outpatient settings

T2 - A case series

AU - Namkoong, Ho

AU - Morimoto, Kozo

AU - Nishimura, Tomoyasu

AU - Tanaka, Hiromu

AU - Sugiura, Hiroaki

AU - Yamada, Yoshitake

AU - Kurosaki, Atsuko

AU - Asakura, Takanori

AU - Suzuki, Shoji

AU - Fujiwara, Hiroshi

AU - Yagi, Kazuma

AU - Ishii, Makoto

AU - Tasaka, Sadatomo

AU - Betsuyaku, Tomoko

AU - Hoshino, Yoshihiko

AU - Kurashima, Atsuyuki

AU - Hasegawa, Naoki

PY - 2016/8/9

Y1 - 2016/8/9

N2 - Background: Mycobacterium abscessus (M. abscessus) pulmonary disease is a refractory chronic infectious disease. Options for treating M. abscessus pulmonary disease are limited, especially in outpatient settings. Among parenteral antibiotics against M. abscessus, intravenous amikacin (AMK) is expected to be an effective outpatient antimicrobial therapy. This study evaluated the clinical efficacy and safety of intravenous AMK therapy in outpatients with M. abscessus pulmonary disease. Methods: This retrospective chart review of cases of M. abscessus pulmonary disease evaluated patient background data, AMK dosage and duration, sputum conversion, clinical symptoms radiological findings, and adverse events. M. massiliense was excluded on the basis of multiplex PCR assay. Results: Thirteen patients (2 men and 11 women) with M. abscessus pulmonary disease were enrolled at 2 hospitals. The median age at the initiation of intravenous AMK treatment was 65 years (range: 50-86 years). Patients received a median AMK dose of 12.5 mg/kg (range: 8.3-16.2 mg/kg) for a median duration of 4 months (range: 3-9 months). The addition of intravenous AMK led to sputum conversion in 10 of 13 patients, and 8 patients continued to have negative sputum status 1 year after treatment. Approximately half of the patients showed improvement on chest high-resolution computed tomography. There were no severe adverse events such as ototoxicity, vestibular toxicity, and renal toxicity. Conclusions: Thrice weekly intravenous AMK administration in outpatient settings is effective and safe for patients with M. abscessus pulmonary disease.

AB - Background: Mycobacterium abscessus (M. abscessus) pulmonary disease is a refractory chronic infectious disease. Options for treating M. abscessus pulmonary disease are limited, especially in outpatient settings. Among parenteral antibiotics against M. abscessus, intravenous amikacin (AMK) is expected to be an effective outpatient antimicrobial therapy. This study evaluated the clinical efficacy and safety of intravenous AMK therapy in outpatients with M. abscessus pulmonary disease. Methods: This retrospective chart review of cases of M. abscessus pulmonary disease evaluated patient background data, AMK dosage and duration, sputum conversion, clinical symptoms radiological findings, and adverse events. M. massiliense was excluded on the basis of multiplex PCR assay. Results: Thirteen patients (2 men and 11 women) with M. abscessus pulmonary disease were enrolled at 2 hospitals. The median age at the initiation of intravenous AMK treatment was 65 years (range: 50-86 years). Patients received a median AMK dose of 12.5 mg/kg (range: 8.3-16.2 mg/kg) for a median duration of 4 months (range: 3-9 months). The addition of intravenous AMK led to sputum conversion in 10 of 13 patients, and 8 patients continued to have negative sputum status 1 year after treatment. Approximately half of the patients showed improvement on chest high-resolution computed tomography. There were no severe adverse events such as ototoxicity, vestibular toxicity, and renal toxicity. Conclusions: Thrice weekly intravenous AMK administration in outpatient settings is effective and safe for patients with M. abscessus pulmonary disease.

KW - Amikacin

KW - Intravenous therapy

KW - Mycobacterium abscessus

KW - Outpatient treatment

KW - Rapid-growing mycobacterium

UR - http://www.scopus.com/inward/record.url?scp=84981200524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84981200524&partnerID=8YFLogxK

U2 - 10.1186/s12879-016-1689-6

DO - 10.1186/s12879-016-1689-6

M3 - Article

C2 - 27506679

AN - SCOPUS:84981200524

VL - 16

JO - BMC Infectious Diseases

JF - BMC Infectious Diseases

SN - 1471-2334

IS - 1

M1 - 396

ER -